Medicine Network May 25th, May 24th, WuXing PharmaTech has reached the 13th daily limit since the listing of the company, with a single quote price of 97.6 yuan. The company's market value has broken 100 billion yuan. Lige and his wife also spent more than 79.6 billion yuan worth of netizens. The richest man.
In the evening of the same day, WuXi PharmaTech issued an announcement indicating risk: the price-to-earnings ratio is higher than the industry. There is also a fund manager's comment. WuXi PharmaTech's valuation has reached more than 60 times. We prefer companies with a P/E of about 20 times.
Physician Mingkang's ultra-thousand billion, becoming the most profitable new shares
As of yesterday, the total market value of Wuxi PharmaTech at the issue price of 21.6 yuan was 101.7 billion yuan. According to statistics, at the same time, Wuxi Meijik Pharmaceutical Co., Ltd. had a profit of 76,000 yuan per contract, and it has become the most profitable new share in the year.
After the demolition of the three, along with the listing of Wuxi Pharmaceutical's A-shares, the total market capitalization of the three companies has exceeded 200 billion yuan.
In August 2007, WuXi PharmaTech was listed on the New York Stock Exchange and withdrew its market value of US$3.3 billion (about RMB 21.092 billion) in December 2015.
After the US stocks were withdrawn from the market, the WuXi MingDang spin-off business was listed separately.
By the end of the 24th, the total market value of the entire pharmaceutical industry was 19.879 billion yuan, and the pharmaceutical market value of Yiming was 98.80 billion Hong Kong dollars (approximately 79.75 billion yuan). The total market value of WuXi PharmaTech was 101.7 billion yuan. At this point, the total market capitalization of the three companies exceeded 200 billion yuan.
In other words, the market value of 'Returnee' WuXi MingKang increased by nearly 10 times in just three years.
According to Forbes' 2018 China Rich List released on March 9th, Li and his wife could rank 21st on the list of the country's richest people with a row of US$12.5 billion, and Hengrui Sun’s wealth on this list is US$8.9 billion. Fosun Guo Guangchang was 8.7 billion U.S. dollars, ranked 31st and 33rd respectively.
In addition to today's market value, WuXi's lightning conference also shows the expectations of the capital market.
On April 24th, WuXi PharmaTech officially launched the A-share IPO. From the pre-disclosure, the prospectus was updated to the previous meeting. It took only 50 days for the meeting, and after more than half a month, the success of the “anti-super” event took only 36 hours. Tian Foxconn took the lead in getting the IPO approval.
Yi Xue and his wife become the richest man in the medical circle
According to public information, Li Ge and Zhao Ning are currently holding a 25% stake in WuXing Kangde Chao and a 67.6% stake in Yaoming Bio.
For WuXi PharmaTech, it was co-founded by Li Ge, Liu Xiaozhong, and Zhang Zhaohui. Together with Zhao Ning, who later joined the company, these four people are the actual controllers of the company. Li Ge and Zhao Ning are couples of Peking University's Leftover Aesthetics. 3. People collectively control 34.48% of the company's voting rights.
The pharmaceutical Ming biological listed in Hong Kong last year, the stock price has risen more than 200% so far, plus the 13 limit limit of the drug Mingkang, Li Ge, Zhao Ning couple's stock market value of the two drug companies were 53.86 billion yuan, 25.77 billion yuan, total about 80 billion yuan.
In other words, along with the dramatic rise in the market value of WuXi PharmaTech, Li Ge and his wife have become the richest man in the Chinese pharmaceutical industry with a turnover of nearly 80 billion. He has surpassed the previous chairman Sun Feiyang of Hengrui Pharmaceuticals, chairman of Fosun, Guo Guangchang, and Kangmei Pharmaceutical Co., Ltd. Xingtian family.
In addition, industry insiders have commented that Hengrui Pharmaceuticals, with a market value of 266.524 billion yuan, will also become the target pursued by WuXi.
According to industry insiders, Hengrui Pharmaceuticals is recognized as a “white horse stock.” The so-called “white horse stocks” refer to stocks that have long-term good performance, high returns, and high investment value. As the relevant information has been made public, the performance is relatively clear. It also has the characteristics of excellent performance, high growth, and low risk. Therefore, it has high investment value and is often favored by investors.
Therefore, it can be said that WuXi PharmaTech has also been placed in high hopes by the market. According to statistics of Wind, since its listing in October 2000, according to the calculation of post-restoration rights, Hengrui medicine The cumulative increase in stock price is over 200 times.
Pharmacopeial Ming Kant will surpass Yunnan Baiyao, Kangmei
In February 2018, Hefei Pharmaceuticals released the 2017 annual performance report. The company's 2017 revenue was 2.189 billion yuan, an increase of 24% year-on-year. The net profit attributable to the shareholders of the listed company was 495 million yuan, a year-on-year increase of 5%.
The drug company's 2017 revenue was 1.619 billion yuan, a year-on-year increase of 63.7%, gross profit of 661 million yuan, a year-on-year increase of 69.8%, and net profit of 253 million yuan, a year-on-year increase of 79%.
According to the prospectus, in the first nine months of 2017, WuXi PharmaTech's revenue was 4.139 billion yuan, 4.883 billion yuan, 6.116 billion yuan, 5.667 billion yuan. The net profit was 808 million yuan respectively. 680 million yuan, 1.12 billion yuan, 1.114 billion yuan; Net profit attributable to the shareholders of the parent company were 461 million yuan, 348 million yuan, 974.93 million yuan, 1.063 billion yuan.
Some analysts believe that from the perspective of revenue, it can be expected that the three companies will enjoy high growth in the future. From a performance point of view, WuXi PharmaTech's stock price will also be well supported.
The famous economist Song Qinghui proposed to the media that WuXi PharmaTech could target the gene giant of the BGI in 2017. The latter had a daily limit of 18 consecutive days and performed extremely eye-catching.
In addition, there are brokerages who believe that the future market value of WuXi PharmaTech can target the other three billion-dollar giants in the pharmaceutical sector.
Among them, the current probability of Yunnan Baiyao with a total market value of 120.917 billion yuan and the current total market value of 134.902 billion yuan will be surpassed by WuXi Pharmaceutical.
